Zevra Therapeutics, Inc. (ZVRA) Stock

Understand Zevra Therapeutics, Inc.: how it makes money

Zevra Therapeutics develops prodrug versions of existing FDA-approved drugs, commercializing Myplifa for Niemann-Pick type C and earning orphan-drug-level pricing per patient in the U.S. market. Nearly all revenue is U.S. Myplifa prescriptions, so growth is a direct function of how many new patients are enrolled each quarter.

Each newly enrolled NPC patient becomes a recurring revenue line at orphan-drug pricing, so the profit engine is pure per-patient enrollment multiplied by a high list price, with no volume discount dynamics.

Business quality (Exceptional): Pre-commercial orphan-drug company with a single launched product, a 144% operating margin (driven by a tiny cost base), and 77.5% revenue growth. Quality is exceptional in the narrow sense that per-patient economics are strong, but the business is still proving itself at scale.

Valuation: At 7× earnings, ZVRA trades 62% below the Pharmaceutical Products average (17×). Note: the low multiple may reflect one-time earnings items.

Bull case

• Enrollment momentum is compounding: Management cited continued U.S. Myplifa sales growth and enrollment momentum on the Q2 FY26 call, with 13 new prescription enrollment forms received this quarter on top of 129 since launch. Each form adds a recurring revenue line, so the base is still building.
• No generic threat through 2041: Orange Book protection for Myplifa extends through 2041, meaning roughly 15 more years of exclusive supply for NPC. That locks in the orphan-drug price point and removes the single biggest structural risk to a niche-gene therapy's revenue stream.
• Grossly below industry valuation: Zevra trades at a P/E of 6.5x versus the Pharmaceutical Products industry average of 17.2x, a 62% discount. Even accounting for the micro-revenue base, the multiple implies the market is pricing in very low confidence in durability, which leaves upside if enrollment keeps compounding.

Bear case

• Europe door closed for now: The CHMP issued a negative opinion on Myplifa, and management acknowledged that European approval remains uncertain. That removes a meaningful geographic expansion path and caps near-term revenue upside to the U.S. market.
• EAP reimbursements are a coin flip: Management warned that non-French Expanded Access Program reimbursements may fluctuate substantially and remain difficult to forecast. When a large share of revenue depends on case-by-case payer approvals rather than formulary listings, quarterly revenue becomes hard to model.
• Pipeline offers no near-term offset: Solifterol, the next-in-line candidate, is still early in its event-driven Phase 3 DiSCOVER trial. Its commercial contribution is years away, so a stumble in Myplifa enrollment or EAP access would leave the company without a second revenue engine.

Zevra Therapeutics, Inc. earnings call transcripts

• ZVRA Q2 FY26 earnings call transcript (reported 2026-08-05) · analysis
• ZVRA Q4 FY25 earnings call transcript (reported 2026-03-09) · analysis

All ZVRA earnings calls

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

• Supernus Pharmaceuticals, Inc. (SUPN)
• Collegium Pharmaceutical, Inc. (COLL)
• Gyre Therapeutics, Inc. (GYRE)
• Nurix Therapeutics, Inc. (NRIX)
• REGENXBIO Inc. (RGNX)
• Eton Pharmaceuticals, Inc. (ETON)
• Agios Pharmaceuticals, Inc. (AGIO)
• Stoke Therapeutics, Inc. (STOK)